NCT00085878View on ClinicalTrials.gov

Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

January 31, 2003

Conditions

Solid Tumor Cancer

Interventions

DRUG

SB-485232

Trial Locations (4)

19111

GSK Investigational Site, Philadelphia

27705

GSK Investigational Site, Durham

46202

GSK Investigational Site, Indianapolis

90404-2104

GSK Investigational Site, Santa Monica

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY